BACKGROUND: A pressing need exists to identify factors that predispose to recurrence after terminal ileal resection for Crohn's disease (CD) and to determine effective prophylactic strategies. This review presents an up-to-date summary of the literature in the field and points to a role for bacterial overproliferation in recurrence. METHODS: The literature (Medline, Embase, and the Cochrane Library, 1971-2009) on ileal CD and postoperative recurrence was searched, and 528 relevant articles were identified and reviewed. RESULTS: Smoking is a key independent risk factor for recurrence. NOD2/CARD15 polymorphisms and penetrating phenotype are associated with aggressive disease and higher reoperation rates. Age at diagnosis, disease duration, gender, and family history are inconsistent predictors of recurrence. Prophylactic 5-aminosalicylic acid therapy and nitromidazole antibiotics are beneficial. Combination therapies with immunosuppressants are also effective. Anti-TNFalpha-based regimens show benefit but the evidence base is small. Corticosteroid, interleukin-10, and probiotic therapies are not effective. Wider, stapled anastomotic configurations are associated with reduced recurrence rates. Strictureplasty and laparoscopic approaches have similar long-term recurrence rates to open resection techniques. Length of resection and presence of microscopic disease at resection margins do not influence recurrence. A lack of consensus exists regarding whether the presence of granulomas or plexitis affects outcome. CONCLUSIONS: Current evidence points to defects in mucosal immunity and intestinal dysbiosis of either innate (NOD2/CARD15) or induced (smoking) origin in postoperative CD recurrence. Prophylactic strategies should aim to limit dysbiosis (antibiotics, side-to-side anastomoses) or prevent downstream chronic inflammatory sequelae (anti-inflammatory, immunosuppressive, and immunomodulatory therapy).
BACKGROUND: A pressing need exists to identify factors that predispose to recurrence after terminal ileal resection for Crohn's disease (CD) and to determine effective prophylactic strategies. This review presents an up-to-date summary of the literature in the field and points to a role for bacterial overproliferation in recurrence. METHODS: The literature (Medline, Embase, and the Cochrane Library, 1971-2009) on ileal CD and postoperative recurrence was searched, and 528 relevant articles were identified and reviewed. RESULTS: Smoking is a key independent risk factor for recurrence. NOD2/CARD15 polymorphisms and penetrating phenotype are associated with aggressive disease and higher reoperation rates. Age at diagnosis, disease duration, gender, and family history are inconsistent predictors of recurrence. Prophylactic 5-aminosalicylic acid therapy and nitromidazole antibiotics are beneficial. Combination therapies with immunosuppressants are also effective. Anti-TNFalpha-based regimens show benefit but the evidence base is small. Corticosteroid, interleukin-10, and probiotic therapies are not effective. Wider, stapled anastomotic configurations are associated with reduced recurrence rates. Strictureplasty and laparoscopic approaches have similar long-term recurrence rates to open resection techniques. Length of resection and presence of microscopic disease at resection margins do not influence recurrence. A lack of consensus exists regarding whether the presence of granulomas or plexitis affects outcome. CONCLUSIONS: Current evidence points to defects in mucosal immunity and intestinal dysbiosis of either innate (NOD2/CARD15) or induced (smoking) origin in postoperative CD recurrence. Prophylactic strategies should aim to limit dysbiosis (antibiotics, side-to-side anastomoses) or prevent downstream chronic inflammatory sequelae (anti-inflammatory, immunosuppressive, and immunomodulatory therapy).
Authors: R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: P J McDonald; V W Fazio; R G Farmer; D G Jagelman; I C Lavery; W B Ruderman; K A Easley; P H Harper Journal: Dis Colon Rectum Date: 1989-02 Impact factor: 4.585
Authors: R Caprilli; M Cottone; F Tonelli; G Sturniolo; F Castiglione; V Annese; C Papi; A Viscido; C Cammà; G Corrao; G Latella Journal: Aliment Pharmacol Ther Date: 2003-02-15 Impact factor: 8.171
Authors: George E Reese; Theodore Nanidis; Catherine Borysiewicz; Takayuki Yamamoto; Timothy Orchard; Paris P Tekkis Journal: Int J Colorectal Dis Date: 2008-09-02 Impact factor: 2.571
Authors: F Botti; A Carrara; B Antonelli; F Quadri; M Maino; B Cesana; E Contessini-Avesani Journal: Ann Ital Chir Date: 2003 Nov-Dec Impact factor: 0.766
Authors: Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present Journal: Gastroenterology Date: 2004-09 Impact factor: 22.682
Authors: Kil Yeon Lee; Chang Sik Yu; Kang Young Lee; Yong Beom Cho; Kyu Joo Park; Gyu-Seog Choi; Sang Nam Yoon; Hanna Yoo Journal: J Korean Soc Coloproctol Date: 2012-08-31
Authors: Calvin J Coffey; Miranda G Kiernan; Shaheel M Sahebally; Awad Jarrar; John P Burke; Patrick A Kiely; Bo Shen; David Waldron; Colin Peirce; Manus Moloney; Maeve Skelly; Paul Tibbitts; Hena Hidayat; Peter N Faul; Vourneen Healy; Peter D O'Leary; Leon G Walsh; Peter Dockery; Ronan P O'Connell; Sean T Martin; Fergus Shanahan; Claudio Fiocchi; Colum P Dunne Journal: J Crohns Colitis Date: 2018-11-09 Impact factor: 9.071
Authors: Ellen Li; Yuanhao Zhang; Xinyu Tian; Xuefeng Wang; Grace Gathungu; Ashley Wolber; Shehzad S Shiekh; R Balfour Sartor; Nicholas O Davidson; Matthew A Ciorba; Wei Zhu; Leah M Nelson; Charles E Robertson; Daniel N Frank Journal: PLoS One Date: 2019-02-28 Impact factor: 3.240
Authors: S Ingallinella; M Campanelli; A Antonelli; C Arcudi; V Bellato; A Divizia; M Franceschilli; L Petagna; B Sensi; S Sibio; L Siragusa; G S Sica Journal: Gastroenterol Res Pract Date: 2020-12-28 Impact factor: 2.260